We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Oxford Biodynamics Plc | LSE:OBD | London | Ordinary Share | GB00BD5H8572 | ORD GBP0.01 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.09 | -0.99% | 9.00 | 8.50 | 9.50 | 8.60 | 8.60 | 8.60 | 672,529 | 16:35:13 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Biological Pds,ex Diagnstics | 1.34M | -10.83M | -0.0535 | -1.61 | 17.4M |
TIDMOBD
RNS Number : 2120J
Oxford BioDynamics PLC
03 December 2018
OXFORD BIODYNAMICS PLC
TOTAL VOTING RIGHTS
London, 3 December 2018: Oxford BioDynamics Plc (AIM: OBD) (the "Company")
In conformity with the FCA's Disclosure Guidance and Transparency Rule 5.6.1, the Company notifies the market that as at 30 November 2018 the Company's total issued share capital consisted of 92,559,771 ordinary shares with one voting right per share. The Company does not hold any ordinary shares in Treasury. Therefore, the total number of voting rights in the Company is 92,559,771.
The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
For further details, contact:
Oxford BioDynamics Plc +44 (0)1865 518910 Christian Hoyer Millar, CEO Paul Stockdale, CFO Shore Capital +44 (0)20 7408 4090 Nominated Advisor and Broker Stephane Auton Edward Mansfield FTI Consulting +44 (0)20 3727 1000 Financial Public Relations Advisor Brett Pollard Natalie Garland-Collins
Notes for Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a biotechnology company focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry.
The Company's award-winning, proprietary technology platform, EpiSwitch(TM), aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine.
In particular, EpiSwitch(TM) can reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re--positioning programmes, and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.
Oxford BioDynamics is headquartered in the UK, and listed on the London Stock Exchange's AIM under the ticker "OBD". For more information please visit www.oxfordbiodynamics.com.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
TVRGMMGZGFNGRZM
(END) Dow Jones Newswires
December 03, 2018 05:10 ET (10:10 GMT)
1 Year Oxford Biodynamics Chart |
1 Month Oxford Biodynamics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions